Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography.
Boron neutron capture therapy (BNCT) is a cancer brachytherapy based upon the thermal neutron reaction: 10B(n,alpha)7Li. The efficacy of the treatment depends primarily upon two conditions being met: (a) the preferential concentration of a boronated compound in the neoplasm and (b) an adequate fluence of thermal neutrons delivered to the neoplasm. The boronated amino acid, para-boronophenylalanine (BPA), is the agent widely used in clinical trials to deliver 10B to the malignancy. Positron emission tomography (PET) can be used to generate in vivo boron distribution maps by labeling BPA with the positron emitting nuclide fluorine-18. The incorporation of the PET-derived boron distribution maps into current treatment planning protocols is shown to provide improved treatment plans. Using previously established protocols, six patients with glioblastoma had 18BPA PET scans. The PET distribution maps obtained were used in the conventional BNCT treatment codes. The isodose curves derived from the PET data are shown to differ both qualitatively and quantitatively from the conventional isodose curves that were derived from calculations based upon the assumption of uniform uptake of the pharmaceutical in tumor and normal brain regions. The clinical course of each of the patients who eventually received BNCT (five of the six patients) was compared using both sets of isodose calculations. The isodose contours based upon PET derived distribution data appear to be more consistent with the patients' clinical course.
Nichols
Trent L
TL
Department of Radiology, The University of Tennessee Memorial Research Center and Hospital, Knoxville 37920, USA. tnichol2@utk.edu
Kabalka
George W
GW
Miller
Laurence F
LF
Khan
Mohammad K
MK
Smith
Gary T
GT
D001896:Boron Compounds / Q000493:pharmacokinetics; D016754:Boron Neutron Capture Therapy / Q000295:instrumentation / Q000379:methods*; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D005462:Fluorine Radioisotopes / Q000627:therapeutic use; D005909:Glioblastoma / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009336:Necrosis; D009502:Neutrons; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011874:Radiometry; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D013997:Time Factors; D014055:Tomography, Emission-Computed / Q000295:instrumentation / Q000379:methods*
D001896:Boron Compounds; D005462:Fluorine Radioisotopes; D010649:Phenylalanine